Emerging Use of BPC 157 in Orthopaedic Sports Medicine: A Systematic Review Nikhil Vasireddi, Henrik Hahamyan, Michael J. Salata, Michael Karns, Jacob G. Calcei, James E. Voos, John M. Apostolakos, 2025 The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York The Peptide Craze Part 2: BPC 157, NAD and the Truth Behind the Longevity Molecule Hype A new FDA advisory panel meeting, influenced by RFK Jr.'s push for broader access, will weigh the potential benefits and risks of widely promoted peptides. Click the link in bio to read FDA to weigh easing limits on unproven peptides promoted by RFK Jr.